mortality/aging
• life span is considerably reduced on average but considerably longer than Faslpr controls
|
immune system
• frequency of CD4+ T cells in peripheral blood is significantly reduced relative to Faslpr controls
• percentage of CD8+ T cells is markedly reduced at 14 and 20 weeks of age relative to Faslpr controls
|
• levels significantly reduced relative to Faslpr controls
|
• levels significantly reduced relative to Faslpr controls
|
• enlargement is significantly less at 14 weeks of age than in Faslpr controls
• spleen enlargement at 20 weeks equivalent to controls
|
• enlargement is significantly less than in Faslpr controls
|
• less T-cell and macrophage infiltration than in Faslpr controls
|
• not as extensive as in Faslpr controls
|
renal/urinary system
albuminuria
(
J:113343
)
• significantly less developed at 8 and 14 weeks but comparable to Faslpr controls at 20 weeks
|
• less T-cell and macrophage infiltration than in Faslpr controls
|
• not as extensive as in Faslpr controls
|
• abnormalities much less than in Faslpr controls
• abnormalities seen at 14 weeks of age include hypercellular glomeruli, increased mesangial matrix, and perivascular lymphoid cell accumulations
|
• increased mesangial matrix at 14 weeks of age
|
• intraglomerular necrosis and sclerosis less developed than in Faslpr controls
|
• tubular damage and atrophy less than in Faslpr controls
|
hematopoietic system
• enlargement is significantly less at 14 weeks of age than in Faslpr controls
• spleen enlargement at 20 weeks equivalent to controls
|
• frequency of CD4+ T cells in peripheral blood is significantly reduced relative to Faslpr controls
• percentage of CD8+ T cells is markedly reduced at 14 and 20 weeks of age relative to Faslpr controls
|
homeostasis/metabolism
• levels significantly reduced relative to Faslpr controls
|
• levels significantly reduced relative to Faslpr controls
|
albuminuria
(
J:113343
)
• significantly less developed at 8 and 14 weeks but comparable to Faslpr controls at 20 weeks
|
growth/size/body
• enlargement is significantly less at 14 weeks of age than in Faslpr controls
• spleen enlargement at 20 weeks equivalent to controls
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
systemic lupus erythematosus | DOID:9074 |
OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420 |
J:113343 |